Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Research Article
10 July 2019

Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice

Authors: Herminio Morillas-Climent, Julia Seller-Moya, Álvaro Vicedo-López, Emilio Galcerá-Jornet, Edgard Alania-Torres, Ydelise Rodríguez-Pichardo, Ainhoa Larumbe-Rodríguez, and Alfonso Valle-Muñoz [email protected]Author Info & Affiliations
Volume 8, Number 9
https://doi.org/10.2217/cer-2019-0014
PDFFormats

Abstract

Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart failure and reduced ejection fraction that started treatment with sacubitril/valsartan. Results: 149 patients (70.7 ± 9.6 years) were included. At baseline, 83.9, 15.4 and 0.7% were taking sacubitril/valsartan 24/26, 49/51 and 97/103 mg, respectively. After 316.1 ± 155.9 days, these numbers moved to 38.9, 39.6, 12.8% (8.7% discontinued). Sacubitril/valsartan improved functional class (from 2.3 ± 0.6 to 1.8 ± 0.5; p < 0.001), increased ejection fraction (from 31.2 ± 7.0 to 37.3 ± 10.5%; p < 0.001) and reduced NT-proBNP (from 3884 ± 4871 to 1975.3 ± 3006.6 pg/ml; p = 0.0001). Rates of any event, cardiovascular death and heart failure hospitalization/decompensation were 13.2 events/100 patient-years. Conclusion: Sacubitril/valsartan is effective and safe in routine practice.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther. Adv. Cardiovasc. Dis. 12, 217–231 (2018).
PubMed
Google Scholar
2.
Yandrapalli S, Andries G, Biswas M, Khera S. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vasc. Health Risk Manag. 13, 369–382 (2017).
PubMed
Google Scholar
3.
Rudiger A, Harjola VP, Muller A et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur. J. Heart Fail. 7, 662–670 (2005).
PubMed
Google Scholar
• Despite current heart failure (HF) therapies, morbidity and mortality of patients hospitalized with acute HF remain high.
4.
Fonarow GC, Abraham WT, Albert NM et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297, 61–70 (2007).
PubMed
Google Scholar
5.
Benjamin EJ, Virani SS, Callaway CW et al. Heart disease and stroke statistics – 2018 update: a report from the American Heart Association. Circulation 137, e67–e492 (2018).
PubMed
Google Scholar
6.
Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr. Heart Fail. Rep. 11, 404–415 (2014).
PubMed
Google Scholar
7.
McMurray JJ, Packer M, Desai AS et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).
PubMed
Google Scholar
•• In the PARADIGM-HF trial, sacubitril/valsartan was superior to enalapril in reducing the risk of death and HF hospitalization among patients with HF and reduced ejection fraction.
8.
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129–2200 (2016).
PubMed
Google Scholar
9.
Ambrosy AP, Mentz RJ, Fiuzat M et al. The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur. J. Heart Fail. 20, 963–972 (2018).
PubMed
Google Scholar
10.
Joly JM, Desai AS. Sacubitril/valsartan: from clinical trials to real-world experience. Curr. Treat. Options Cardiovasc. Med. 20, 45 (2018).
PubMed
Google Scholar
11.
Sciatti E, Senni M, Lombardi CM, Gori M, Metra M. Sacubitril/valsartan: from a large clinical trial to clinical practice. J. Cardiovasc. Med. (Hagerstown) 19, 473–479 (2018).
PubMed
Google Scholar
12.
Fontes-Carvalho R. Sacubitril–valsartan in the real world: from theory to clinical practice. Rev. Port. Cardiol. 37, 497–498 (2018).
PubMed
Google Scholar
13.
Rodrigues G, Tralhão A, Aguiar C, Freitas P, Ventosa A, Mendes M. Is the PARADIGM-HF cohort representative of the real-world heart failure patient population? Rev. Port. Cardiol. 37, 491–496 (2018).
PubMed
Google Scholar
• In this cohort, only one in four patients with systolic HF fulfilled criteria for the PARADIGM-HF trial.
14.
Barrios V, Escobar C, Pallares V et al. Management of heart failure in cardiology and primary care (MICCAP) program: improving the management of patients with heart failure. Semergen 44(8), 572–578 (2018).
PubMed
Google Scholar
15.
Gagne JJ, Tsacogianis T, Bruce Wirta S et al. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. J. Comp. Eff. Res. 7(11), 1073–1082 (2018).
PubMed
Google Scholar
16.
Rodil Fraile R, Malafarina V, Tiberio López G. Sacubitril–valsartan in heart failure and multimorbidity patients. ESC Heart Fail. 5(5), 956–959 (2018).
PubMed
Google Scholar
17.
DeVore AD, Mi X, Thomas L et al. Characteristics and treatments of patients enrolled in the CHAMP-HF registry compared with patients enrolled in the PARADIGM-HF trial. J. Am. Heart Assoc. 7(12), pii: e009237 (2018).
Google Scholar
18.
Vicent L, Esteban-Fernández A, Gómez-Bueno M et al. Clinical profile of a nonselected population treated with sacubitril/valsartan is different from PARADIGM-HF trial. J. Cardiovasc. Pharmacol. 72, 112–116 (2018).
PubMed
Google Scholar
19.
Antol DD, Casebeer AW, DeClue RW, Stemkowski S, Russo PA. An early view of real-world patient response to sacubitril/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction. Adv. Ther. 35, 785–795 (2018).
PubMed
Google Scholar
• In clinical practice, sacubitril/valsartan improves symptoms and reduces hospitalizations.
20.
Wachter R, Viriato D, Klebs S et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad. Med. 130, 308–316 (2018).
PubMed
Google Scholar
• Despite baseline demographics and clinical characteristics being similar to those from PARADIGM-HF trial, most patients were initiated on the lowest dose.
21.
Vincenzi A, Cesana F, Cirò A, Garatti L, Achilli F. Sacubitril/valsartan in “field practice” patients with advanced heart failure: a monocentric Italian experience. Cardiology 138(Suppl. 1), 13–16 (2017).
PubMed
Google Scholar
22.
Kałużna-Oleksy M, Kolasa J, Migaj J et al. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class – angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kardiol. Pol. 76, 381–387 (2018).
PubMed
Google Scholar
23.
Norberg H, Bergdahl E, Lindmark K. Eligibility of sacubitril–valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail. 5, 337–343 (2018).
PubMed
Google Scholar
24.
Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM. Adoption of sacubitril/valsartan for the management of patients with heart failure. Circ. Heart Fail. 11, e004302 (2018).
PubMed
Google Scholar
25.
Tsutsui H, Momomura SI, Saito Y et al. Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction – baseline characteristics and treatment of PARALLEL-HF trial. Circ. J. 82(10), 2575–2583 (2018).
PubMed
Google Scholar
26.
European Medicines Agency Summary of product characteristics of sacubitril/valsartan. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf
Google Scholar
27.
Senni M, McMurray JJV, Wachter R et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur. J. Heart Fail. 20, 491–500 (2018).
PubMed
Google Scholar
•• Low systolic blood pressure should not avoid the initiation of sacubitril/valsartan when titration is performed gradually.
28.
Laflamme É, Vachon A, Gilbert S et al. Usefulness of a titration algorithm for de novo users of sacubitril/valsartan in a tertiary centre heart failure clinic. Cardiovasc. J. Afr. 29, 1–5 (2018).
Google Scholar
29.
Lewis EF, Claggett BL, McMurray JJV et al. Health-related quality of life outcomes in PARADIGM-HF. Circ. Heart Fail. 10(8), pii: e003430 (2017).
Google Scholar
30.
Chandra A, Lewis EF, Claggett BL et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 3, 498–505 (2018).
PubMed
Google Scholar
31.
Sgorbini L, Rossetti A, Galati A. Sacubitril/valsartan: effect on walking test and physical capability. Cardiology 138(Suppl. 1), 17–20 (2017).
PubMed
Google Scholar
32.
Beltrán P, Palau P, Domínguez E et al. Sacubitril/valsartan and short-term changes in the 6-minute walk test: a pilot study. Int. J. Cardiol. 252, 136–139 (2018).
PubMed
Google Scholar
33.
Anand I. Stable but progressive nature of heart failure: considerations for primary care physicians. Am. J. Cardiovasc. Drugs 18(5), 333–345 (2018).
PubMed
Google Scholar
34.
Suematsu Y, Jing W, Nunes A et al. LCZ696 (sacubitril/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J. Card. Fail. 24, 266–275 (2018).
PubMed
Google Scholar
35.
Jing W, Vaziri ND, Nunes A et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am. J. Transl. Res. 9, 5473–5484 (2017).
PubMed
Google Scholar
36.
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc. Ther. 36, e12435 (2018).
PubMed
Google Scholar
37.
Januzzi JL, Butler J, Fombu E et al. Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril/valsartan therapy for heart failure (PROVE-HF). Am. Heart J. 199, 130–136 (2018).
PubMed
Google Scholar
38.
Almufleh A, Marbach J, Chih S et al. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients. Am. J. Cardiovasc. Dis. 7, 108–113 (2017).
PubMed
Google Scholar
39.
Núñez J, Llàcer P, Bertomeu-González V et al. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail. 4, 833–843 (2016).
PubMed
Google Scholar
40.
Pogge EK, Davis LE. Evaluating the safety and tolerability of sacubitril/valsartan for HFrEF managed within a pharmacist clinic. Am. J. Cardiovasc. Drugs 18, 143–151 (2018).
PubMed
Google Scholar
41.
Moulis F, Rousseau V, Chebane L et al. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey. Eur. J. Clin. Pharmacol. 74, 983–984 (2018).
PubMed
Google Scholar
42.
De Vecchis R, Ariano C, Di Biase G, Noutsias M. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study. Herz (2018) (Epub ahead of print).
Crossref
Google Scholar
43.
Martens P, Lambeets S, Lau C, Dupont M, Mullens W. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions. Acta Cardiol. 74(2), 115–122 (2019).
PubMed
Google Scholar
• In clinical practice, sacubitril/valsartan is associated with a reduction of HF hospitalizations, but higher doses might be associated with greater reductions.
44.
de Diego C, González-Torres L, Núñez JM et al. Effects of angiotensin–neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm 15, 395–402 (2018).
PubMed
Google Scholar
|